We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+56.2%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$178M
AUM Growth
+$28.4M
Cap. Flow
-$14.1M
Cap. Flow %
-7.93%
Top 10 Hldgs %
56.23%
Holding
58
New
12
Increased
14
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.29M
2
TRML
Tourmaline Bio
TRML
+$4.64M
3
OCUL icon
Ocular Therapeutix
OCUL
+$3.87M
4
RVMD icon
Revolution Medicines
RVMD
+$3.84M
5
MRSN
Mersana Therapeutics
MRSN
+$3.65M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$8.54M
2
VTYX
Ventyx Biosciences
VTYX
+$7.13M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.31M
4
ALKS icon
Alkermes
ALKS
+$3.54M
5
REPL icon
Replimune Group
REPL
+$2.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$23.5M 13.23%
378,069
+33,498
+10% +$833K
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
$11.6M 6.54%
492,155
+74,155
+18% +$1.32M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$372M
$11M 6.17%
366,015
+4,015
+1% +$88.6K
KURA icon
4
Kura Oncology
KURA
$816M
$10.1M 5.68%
701,349
-744
-0.1% -$7.32K
EYPT icon
5
EyePoint Inc
EYPT
$1.04B
$9.82M 5.53%
425,128
+125,000
+42% +$1.4M
PCVX icon
6
Vaxcyte
PCVX
$7.73B
$7.37M 4.15%
117,373
-3,649
-3% -$190K
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.68B
$6.81M 3.83%
70,600
+55,100
+355% +$5.29M
PRAX icon
8
Praxis Precision Medicines
PRAX
$8.52B
$6.68M 3.76%
299,636
+636
+0.2% +$11.5K
IRON icon
9
Disc Medicine
IRON
$2.93B
$6.67M 3.76%
115,500
-22,698
-16% -$1.16M
TSHA icon
10
Taysha Gene Therapies
TSHA
$1.66B
$6.35M 3.58%
3,589,333
-238,593
-6% -$476K
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$6.13M 3.45%
281,500
+57,161
+25% +$902K
TRML
12
DELISTED
Tourmaline Bio
TRML
$6.07M 3.42%
+231,882
New +$4.64M
OCUL icon
13
Ocular Therapeutix
OCUL
$1.84B
$5.84M 3.29%
+1,310,000
New +$3.87M
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$5.49M 3.09%
94,720
+90,736
+2,278% +$3.65M
HLVX
15
DELISTED
HilleVax
HLVX
$5.21M 2.93%
324,600
+54,281
+20% +$721K
IMVT icon
16
Immunovant
IMVT
$7.91B
$5.03M 2.83%
119,489
-9,511
-7% -$350K
RVMD icon
17
Revolution Medicines
RVMD
$38.8B
$4.59M 2.58%
+160,000
New +$3.84M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$4.56M 2.56%
76,100
-168,384
-69% -$8.54M
ACLX
19
DELISTED
Arcellx
ACLX
$4.27M 2.41%
+77,000
New +$3.47M
WHWK
20
Whitehawk Therapeutics
WHWK
$196M
$3.74M 2.1%
1,849,402
– –
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
$3.6M 2.03%
555,260
– –
CRNX icon
22
Crinetics Pharmaceuticals
CRNX
$8.87B
$3.11M 1.75%
87,500
-6,500
-7% -$199K
CLDX icon
23
Celldex Therapeutics
CLDX
$2.96B
$2.75M 1.55%
69,400
-52,941
-43% -$1.56M
ANTX icon
24
AN2 Therapeutics
ANTX
$201M
$2.7M 1.52%
132,000
+118,700
+892% +$1.99M
DYN icon
25
Dyne Therapeutics
DYN
$4.71B
$1.97M 1.11%
147,836
+1,336
+0.9% +$13.1K
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Acuta Capital Partners held 58 positions worth $178M, up 19% from $149M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners withdrew a net $14.1M in Q4 2023, closing 19 positions and reducing 9 holdings. Its most notable exit was Ventyx Biosciences, an estimated $7.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Tourmaline Bio worth $6.07M.

  • Acuta Capital Partners's largest Q4 2023 buy was Tourmaline Bio: 231,882 shares worth $6.07M.
  • Acuta Capital Partners added most to Sarepta Therapeutics in Q4 2023, an estimated $5.29M increase.
  • Acuta Capital Partners's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $8.54M.
  • Acuta Capital Partners fully exited Ventyx Biosciences in Q4 2023, selling an estimated $7.13M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $178M portfolio in Q4 2023.
  • Acuta Capital Partners opened 12 new positions and closed 19 in Q4 2023.
  • Acuta Capital Partners's portfolio value rose 19% quarter-over-quarter to $178M.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.